source
- Argenx’s FB102 meets primary endpoint in phase 2 celiac trial, paving way for pivotal studyArgenx reported that its experimental antibody FB102 achieved a statistically significant improvement in villus height‑to‑crypt depth (Vh:Cd) compared with placebo in a phase 2 study of adults with…
- Rare disease biotech firms expand teams as FDA approvals boost pipelinesSeveral biotech companies focused on rare diseases are actively hiring, offering opportunities for professionals interested in this niche therapeutic area. The article highlights four firms that ar…